Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans
Summary
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and paired the filing with plans to sell parts of its gene therapy development programs. The company identified potential buyers including Eli Lilly and Astellas Pharma. This signals a restructuring process rather than a normal operating announcement. The story matters to life sciences vendors and partners because it may lead to asset sales, diligence, integration, or transition work around the company’s programs and data.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected